On Tuesday, Silexion Therapeutics Corp. SLXN launched new preclinical information for SIL-204, its next-generation siRNA therapeutic candidate.
- SIL-204, administered in an extended-release formulation, decreased tumor progress by ~50% after 30 days, with ~50% of tumors displaying full necrosis in human pancreatic tumors harboring a G12D mutation xenografted into mice.
- SIL-204 administered subcutaneously inhibited tumor progress in mouse metastatic pancreatic orthotopic fashions.
- A single systemic administration of SIL-204 maintained efficient drug ranges in rat plasma and tissues for over 56 days.
- SIL-204 inhibits key oncogenic KRAS mutations, together with G12D, G12V, G12R, Q61H, and G13D.
- Intratumoral administration of SIL-204 microparticles decreased tumor cell numbers by ~3-fold, tumor space by ~1.5-fold, and elevated tumor necrosis by ~5-fold after 15 days in human pancreatic most cancers xenograft harboring a KRAS G12V mutation in mice.
Additionally Learn: Silexion Therapeutics Highlights New Preclinical Information From Its Pancreatic Most cancers Research
The findings contribute to validating systemic administration as an efficient supply strategy, demonstrating important tumor progress discount in orthotopic pancreatic most cancers fashions.
Whereas the present information reveals sturdy tumor progress inhibition, additional research intention to guage its affect on metastases, which the corporate is cautiously optimistic about.
The corporate is exploring how this promising information can inform an expanded next-generation remedy technique for KRAS-driven cancers. It expects to announce particulars of its expanded growth plan shortly.
Value Motion: SLXN inventory is up 130.2% at $1.33 finally test Tuesday.
Learn Subsequent:
Photograph by way of Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
